Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Conditions
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Malignant Glioma
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma
- Recurrent Glioma
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Primary Central Nervous System Neoplasm
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Primary Central Nervous System Neoplasm
- Rhabdoid Tumor
- Stage III Osteosarcoma AJCC v7
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Osteosarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Stage IVA Osteosarcoma AJCC v7
- Stage IVB Osteosarcoma AJCC v7
- Wilms Tumor
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- PROCEDURE: FDG-Positron Emission Tomography
- PROCEDURE: Magnetic Resonance Imaging
- DRUG: Samotolisib
- PROCEDURE: X-Ray Imaging
Sponsor
National Cancer Institute (NCI)